Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: A single-arm phase II study
International Journal of Cancer, 04/24/2012
Clinical Article
Vermeij R et al. – The outcome of the phase II trial warrants new studies on the use of low–dose cyclophosphamide to potentiate the immunogenicity of the p53–SLP vaccine or other antitumor vaccines.



